Both Cellectis S.A. (NASDAQ:CLLS) and Denali Therapeutics Inc. (NASDAQ:DNLI) are Biotechnology companies, competing one another. We will compare their analyst recommendations, institutional ownership, profitability, risk, dividends, earnings and valuation.

Earnings & Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellectis S.A.	25.47M	31.63	82.53M	-2.11	0.00
Denali Therapeutics Inc.	3.48M	594.44	136.66M	-1.45	0.00

Demonstrates Cellectis S.A. and Denali Therapeutics Inc. earnings per share, top-line revenue and valuation.

Profitability

Table 2 has Cellectis S.A. and Denali Therapeutics Inc.’s return on assets, return on equity and net margins.

	Net Margins	Return on Equity	Return on Assets
Cellectis S.A.	-324.03%	-23%	-18.8%
Denali Therapeutics Inc.	-3,927.01%	-27.9%	-24.7%

Liquidity

The Current Ratio and Quick Ratio of Cellectis S.A. are 11.2 and 11.2 respectively. Its competitor Denali Therapeutics Inc.’s Current Ratio is 12.1 and its Quick Ratio is 12.1. Denali Therapeutics Inc. can pay off short and long-term obligations better than Cellectis S.A.

Analyst Ratings

Cellectis S.A. and Denali Therapeutics Inc. Ratings and Recommendations are available on the next table.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Cellectis S.A.	0	1	0	2.00
Denali Therapeutics Inc.	0	0	0	0.00

Cellectis S.A. has an average price target of $25, and a 31.23% upside potential.

Institutional and Insider Ownership

Institutional investors held 29.4% of Cellectis S.A. shares and 84.5% of Denali Therapeutics Inc. shares. On the other hand, insiders held about 0.1% of Denali Therapeutics Inc.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Cellectis S.A.	12.66%	10.81%	-10.39%	-33.67%	-37.98%	17.6%
Denali Therapeutics Inc.	-0.05%	15.48%	14.34%	22.14%	2.04%	6.53%

For the past year Cellectis S.A. was more bullish than Denali Therapeutics Inc.

Summary

Cellectis S.A. beats on 8 of the 11 factors Denali Therapeutics Inc.

Cellectis S.A., a gene-editing company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company operates through two segments, Therapeutics and Plants. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia (ALL) and CLL. The companyÂ’s products also comprise UCART123 for acute myeloid leukemia indications and blastic plasmacytoid dendritic cell neoplasm; UCARTCS1 for multiple myeloma (MM) indications; UCART22 for ALL; and UCART38 for T-cell ALL and MM. In addition, it focuses on applying its gene-editing technologies to develop new generation plant products in the field of agricultural biotechnology. The company has strategic alliances with Pfizer Inc. to generate CAR T-cells in the field of oncology; Les Laboratoires Servier SAS to develop and commercialize product candidates; The University of Texas MD Anderson Cancer Center to research and develop novel cellular immunotherapies for patients suffering from various liquid tumors; and Cornell University to accelerate the development of a targeted immunotherapy for patients with acute myeloid leukemia. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Denali Therapeutics Inc., a biopharmaceutical company, engages in discovering and developing therapeutics for neurodegenerative diseases in the United States. The company's lead LRRK2 product candidates includes the DNL201, a small molecule inhibitor that is in Phase I clinical trials, as well as DNL151, a small molecule inhibitor, which is in preclinical development stage for the treatment of Parkinson's disease. It is also developing therapeutics for the treatment of Parkinson's, dementia with Lewy bodies, and multiple system atrophy; amyotrophic lateral sclerosis; and mucopolysaccharidosis type II patients. Denali Therapeutics Inc. has collaboration agreement with Takeda Pharmaceutical Company to develop and commercialize therapeutic product candidates for neurodegenerative diseases; and a strategic partnership with Lonza Pharma & Biotech to develop and produce biologic medicines for neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.